C84.09 Insurance Policy Changes

ICD-10 C84.09 is officially defined as "Mycosis fungoides, extranodal and solid organ sites." code C84.09 is referenced in 6 tracked payer policy changes from Excellus BlueCross BlueShield, Aetna, and 1 other payer. For billers and coders, staying current on payer-specific coverage criteria, reimbursement rules, and prior-authorization requirements for code C84.09 is critical to clean claim submission. Each entry below links to the full policy analysis with effective dates and action steps.

Excellus BlueCross BlueShield · Effective Oct 22, 2026Medium impact
Extracorporeal Photochemotherapy/Photopheresis 8.01.01
Policy 8.01.01 considers extracorporeal photopheresis medically appropriate for palliative treatment of skin manifestations of cutaneous T-cell lymphoma or Sézary syndrome that have not responded to other therapy, for acute and chronic extensive graft-versus-host disease refractory to conventional therapy, and for recurrent or refractory cardiac allograft rejection. Photopheresis is considered investigational for all other indications, including GVHD in previously untreated patients or those responding to conventional therapy, scleroderma, autoimmune diseases, Crohn's disease, solid organ allograft rejection other than the heart, and diabetes mellitus. The current effective date is October 22, 2026, and the 10/22/26 annual review left the policy intent unchanged.
Aetna · Identified Oct 3, 2026Medium impact
Interferons (CPB 0404, reviewed 2026-09-10)
Aetna's interferon policy covers Actimmune (interferon gamma-1b) for chronic granulomatous disease, mycosis fungoides/Sezary syndrome and severe malignant osteopetrosis, and considers all other indications experimental, investigational, or unproven. Pegasys (peginterferon alfa-2a) and Besremi (ropeginterferon alfa-2b-njft) each have their own list of covered indications, and several Besremi indications are covered only when Pegasys is unavailable. Aetna considers continuation of therapy medically necessary for members who are experiencing benefit, as evidenced by disease stability or disease improvement, and the Biojector 2000 needle-free injection system is considered a medically necessary alternative to needles for members with exacerbating-remitting MS who cannot safely self-inject due to tremors and decreased coordination.
Aetna · Identified Sep 30, 2026Medium impact
Pralatrexate (CPB 0740, reviewed 2026-09-10)
Aetna's clinical policy bulletin for pralatrexate (Folotyn or generic pralatrexate) considers it medically necessary for adult T-cell leukemia/lymphoma, breast implant-associated anaplastic large cell lymphoma, cutaneous anaplastic large cell lymphoma, extranodal NK/T-cell lymphoma, hepatosplenic T-cell lymphoma, mycosis fungoides or Sezary syndrome, peripheral T-cell lymphoma, and subcutaneous panniculitis-like T-cell lymphoma when the listed criteria are met. Most of these indications require use as a single agent, and several also set line-of-therapy or response requirements. Continuation is considered medically necessary when there is no evidence of unacceptable toxicity or disease progression, and all other indications, including multiple myeloma, non-small cell lung carcinoma and solid tumors, are considered experimental, investigational, or unproven.
Aetna · Identified Aug 18, 2026Medium impact
Laser Treatment for Psoriasis and Other Selected Skin Conditions (CPB 0577, reviewed 2026-07-15)
Aetna considers excimer and pulsed dye laser treatment medically necessary for persons with mild-to-moderate localized plaque psoriasis affecting 10% or less of body area who have failed to adequately respond to 3 or more months of topical treatments, including at least 3 of the listed agents. No more than 13 laser treatments per course and 3 courses per year are generally considered medically necessary, and additional courses are not considered medically necessary if the person fails to respond to an initial course, as documented by a reduction in PASI score or other objective response measurement. The policy also covers laser hair removal for recurrent pilonidal cyst, laser treatment for acne keloidalis nuchae and penile intraepithelial neoplasia, and Nd:YAG laser for hidradenitis suppurativa. Combined pulsed dye laser and UVB for localized plaque psoriasis, and excimer or pulsed dye laser for psoriasis other than plaque psoriasis, are considered experimental, investigational or unproven, as is laser treatment for the other listed skin conditions. Laser treatment for acne scarring, keratosis pilaris, pearly penile papules and rhinophyma is considered cosmetic.
Aetna · Identified Aug 16, 2026Medium impact
Mogamulizumab-kpkc (Poteligeo) (CPB 0940, reviewed 2026-04-28)
Aetna considers mogamulizumab-kpkc (Poteligeo) intravenous infusion medically necessary for adult T-cell leukemia/lymphoma (ATLL) when used as a single agent for subsequent therapy for chronic high risk, acute, or lymphoma subtypes, or in combination with CHOP if there is no intention to proceed to transplant. It is also medically necessary for mycosis fungoides (MF) or Sézary syndrome (SS). Continuation is medically necessary when there is no evidence of unacceptable toxicity or disease progression on the current regimen, and all other indications are considered experimental, investigational, or unproven.
Blue Cross & Blue Shield of Mississippi · Identified Jun 20, 2026Medium impact
Extracorporeal Photopheresis
Extracorporeal photopheresis may be considered medically necessary to treat cardiac allograft rejection that is recurrent or refractory to standard immunosuppressive drug treatment, and to treat acute or chronic graft-versus-host disease that is refractory to medical therapy. It may also be considered medically necessary for late-stage (III or IV) cutaneous T-cell lymphoma and for early-stage (I or II) cutaneous T-cell lymphoma that is progressive and refractory to established nonsystemic therapies. Other solid organ rejection uses, graft-versus-host disease that is previously untreated or responding to established therapies, early-stage cutaneous T-cell lymphoma that is untreated or responsive to established nonsystemic therapies, autoimmune diseases, and all other indications are considered investigational.

Watch C84.09

Get one email when a payer policy names C84.09, a payer adds or drops it from a prior auth list, or Medicare changes its NCCI pairs, unit limit, payment or coverage articles.

No account needed. We send a confirmation link first, and every email has a one-click stop link.

FREQUENTLY ASKED QUESTIONS

What insurance policy changes affect code C84.09?

There are 6 tracked policy changes affecting code C84.09, including updates from Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi. Each change may modify coverage criteria, reimbursement rates, or prior-authorization requirements.

Which payers have updated policy for code C84.09?

Payers that have issued tracked updates for code C84.09 include: Excellus BlueCross BlueShield, Aetna, Blue Cross & Blue Shield of Mississippi.

How do I get notified when code C84.09 policy changes?

Create a free account at PolicyChanges.app and save a search filtered to code C84.09. You will get an email when new policy changes reference this code: daily or weekly, your choice, on every plan.

Why do payers change policies for code C84.09?

Payers revise policies for individual billing codes to align with updated clinical guidelines, CMS rule changes, fraud and abuse prevention measures, or network cost-management goals. Changes can affect medical necessity criteria, place-of-service restrictions, bundling rules, or whether a code requires prior authorization.

All billing codes J3590 C9399 J3490 99215 99213 99202

Get alerts for changes like this

Save a search and get email alerts when a new policy change matches your filters: daily or weekly, your choice, on every plan.

Create a free alert How Policy Monitoring works

Extracorporeal Photochemotherapy/Photopheresis 8.01.01

Interferons (CPB 0404, reviewed 2026-09-10)

Pralatrexate (CPB 0740, reviewed 2026-09-10)

Laser Treatment for Psoriasis and Other Selected Skin Conditions (CPB 0577, reviewed 2026-07-15)

Mogamulizumab-kpkc (Poteligeo) (CPB 0940, reviewed 2026-04-28)

Extracorporeal Photopheresis

What insurance policy changes affect code C84.09?

Which payers have updated policy for code C84.09?

How do I get notified when code C84.09 policy changes?

Why do payers change policies for code C84.09?